{"id":701599,"date":"2022-10-27T06:52:50","date_gmt":"2022-10-27T10:52:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/"},"modified":"2022-10-27T06:52:50","modified_gmt":"2022-10-27T10:52:50","slug":"immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/","title":{"rendered":"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n \u2013 Webcast to be Held at 8:00 am ET<\/span> on November 3, 2022<\/span> \u2013<\/i>\n <\/p>\n

\n
\n NEW YORK<\/span>
\n <\/span>, Oct. 27, 2022<\/span><\/span> \/PRNewswire\/ —\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0<\/b>a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022<\/span>, including a corporate update, on Thursday, November 3, 2022<\/span>, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET<\/span>.<\/p>\n

To participate in the webcast, please register in advance at: https:\/\/imux.zoom.us\/webinar\/register\/WN_g6raQxUTRQuuryWUU4Umig<\/a>\u00a0or on the “Events and Presentations” section of Immunic’s website at: ir.imux.com\/events-and-presentations<\/a>. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.<\/p>\n

An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com\/events-and-presentations<\/a>.<\/p>\n

\n About Immunic, Inc.
<\/b>Immunic, Inc. (<\/span>Nasdaq: <\/span>IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and <\/span>autoimmune diseases. The company is developing three small molecule products: its lead development program, <\/span>vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme <\/span>DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, and primary <\/span>sclerosing cholangitis. IMU-935, a selective inverse <\/span>agonist of the transcription factor <\/span>ROR\u03b3\/<\/span>ROR\u03b3<\/span>t, is targeted for development in psoriasis, and castration-resistant prostate cancer. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit:\u00a0<\/span>www.imux.com<\/a>.<\/span><\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements
<\/b>
\n This press release\u00a0contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to <\/span>Immunic’s three development programs and the targeted diseases; the potential for <\/span>Immunic’s development programs to safely and effectively target diseases; preclinical and clinical data for <\/span>Immunic’s development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. <\/span>Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, impacts of the Ukraine<\/span> \u2013 Russia<\/span> conflict on clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by <\/span>Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended\u00a0December 31, 2021, filed with the SEC on\u00a0February 24, 2022, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at <\/span>www.sec.<\/span>gov or <\/span>ir.<\/span>imux.<\/span>com\/sec-filings.\u00a0Any forward-looking statement made in this release speaks only as of the date of this release. <\/span>Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. <\/span>Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.<\/span><\/p>\n

\n Contact Information<\/b>\n <\/p>\n

\n Immunic, Inc.<\/b>
\n
\n Jessica Breu<\/span>
\n
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com<\/a><\/p>\n

\n US IR Contact
<\/b>Rx Communications Group
Paula Schwartz<\/span>
+1 917 633 7790
immunic@rxir.com<\/a><\/u><\/p>\n

\n US Media Contact
<\/b>KOGS Communication
Edna Kaplan<\/span>
+1 617 974 8659
<\/span>kaplan@kogspr.com<\/a><\/u><\/p>\n

\n

\n
\n \"Immunic,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update-301660996.html<\/a><\/p>\n

SOURCE Immunic, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire \u2013 Webcast to be Held at 8:00 am ET on November 3, 2022 \u2013 NEW YORK , Oct. 27, 2022 \/PRNewswire\/ —\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https:\/\/imux.zoom.us\/webinar\/register\/WN_g6raQxUTRQuuryWUU4Umig\u00a0or on the “Events and Presentations” section of Immunic’s website at: ir.imux.com\/events-and-presentations. Registrants will receive a confirmation email containing a link … <\/p>\n

Continue reading “Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701599","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire \u2013 Webcast to be Held at 8:00 am ET on November 3, 2022 \u2013 NEW YORK , Oct. 27, 2022 \/PRNewswire\/ —\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https:\/\/imux.zoom.us\/webinar\/register\/WN_g6raQxUTRQuuryWUU4Umig\u00a0or on the “Events and Presentations” section of Immunic’s website at: ir.imux.com\/events-and-presentations. Registrants will receive a confirmation email containing a link … Continue reading "Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T10:52:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update\",\"datePublished\":\"2022-10-27T10:52:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/\"},\"wordCount\":816,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/\",\"name\":\"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"datePublished\":\"2022-10-27T10:52:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Market Newsdesk","og_description":"PR Newswire \u2013 Webcast to be Held at 8:00 am ET on November 3, 2022 \u2013 NEW YORK , Oct. 27, 2022 \/PRNewswire\/ —\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https:\/\/imux.zoom.us\/webinar\/register\/WN_g6raQxUTRQuuryWUU4Umig\u00a0or on the “Events and Presentations” section of Immunic’s website at: ir.imux.com\/events-and-presentations. Registrants will receive a confirmation email containing a link … Continue reading \"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T10:52:50+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update","datePublished":"2022-10-27T10:52:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/"},"wordCount":816,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/","name":"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","datePublished":"2022-10-27T10:52:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-and-provide-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701599"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701599\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}